InventisBio (SH:688382) 智通财经网·2026-01-02 02:38Company Overview - Yifang Biotechnology (Shanghai) Co., Ltd. is a research-driven biopharmaceutical company based in China, focusing on significant unmet medical needs in oncology, autoimmune diseases, and metabolic disorders [5] - The company has established a comprehensive and differentiated product pipeline, including two commercialized products (BPI-D0316 and D-1553), two core clinical-stage products (D-2570 and D-0502), one clinical-stage candidate (D-0120), and three preclinical candidates (YF087, YF550, and YF057) [5][6] - BPI-D0316, a third-generation EGFR inhibitor, and D-1553, a KRAS G12C inhibitor, have been approved for marketing in China and included in the National Reimbursement Drug List (NRDL) [5][6] Financial Performance - For the fiscal year ending December 31, 2024, the company reported revenues of approximately RMB 168.79 million, with a gross profit of RMB 164.77 million [8][9] - The company recorded a net loss of approximately RMB 240.20 million for the same period [10] - As of September 30, 2025, the company achieved revenues of approximately RMB 30.89 million, with a gross profit of RMB 26.74 million, and a net loss of approximately RMB 181.39 million [8][10] Customer Dependency - The company has a high customer dependency, with revenues from its largest customer accounting for 90.3% and 73.6% of total revenues for the fiscal years ending December 31, 2024, and September 30, 2025, respectively [7] Industry Overview - The global oncology drug market is projected to grow from USD 143.5 billion in 2019 to USD 253.3 billion by 2024, with a compound annual growth rate (CAGR) of 12.0%, and expected to reach USD 702.7 billion by 2035 [12] - The Chinese oncology drug market is expected to grow from USD 26.5 billion in 2019 to USD 35.9 billion by 2024, with a CAGR of 6.3%, and projected to reach USD 145 billion by 2035 [12] - The global targeted oncology drug market is anticipated to grow from USD 85.5 billion in 2019 to USD 154 billion by 2024, with a CAGR of 12.5%, and expected to reach USD 320.5 billion by 2035 [14] - The Chinese targeted oncology drug market is expected to grow from USD 6.2 billion in 2019 to USD 16.6 billion by 2024, with a CAGR of 21.8%, and projected to reach USD 61.6 billion by 2035 [14]